Methylglyoxal, advanced glycation end products and autism: Is there a connection?

Medical Hypotheses

Volumn 78, Issue 4, 2012, Pages 548-552

  Maher, P ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUTATHIONE; GLYOXALASE; GLYOXALASE 1; METHYLGLYOXAL; UNCLASSIFIED DRUG;

ARTICLE; AUTISM; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; FOOD INTAKE; GLUTATHIONE METABOLISM; HUMAN; INFLAMMATION; MATERNAL BLOOD; NEUROLOGIC DISEASE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS;

AUTISTIC DISORDER; FEMALE; GLUTATHIONE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PYRUVALDEHYDE;

EID: 84858153123     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.01.032     Document Type: Article

References (62)

1. Herbert M.R. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010, 23:103-110.
2. Hallmayer J., Cleveland S., Torres A., Phillips J., Cohen B., et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011, 10.1001/archgenpsychiatry.2011.7.
3. Frith U., Happe F. Autism spectrum disorder. Curr Biol 2005, 15:R786-R790.
4. Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiol 2006, 13:171-181.
5. Parker-Athill E.C., Tan J. Maternal immune activation and autism spectrum disorder: interleukin-6 signaling as a key mechanistic pathway. Neurosignals 2010, 18:113-128.
6. Palmieri L., Persico A.M. Mitochondrial dysfunction in autism spectrum disorders: cause or effect?. Biochim Biophys Acta 2010, 1797:1130-1137.
7. Lewerenz J., Maher P. Control of redox state and redox signaling by neural antioxidant systems. Antioxid Redox Signal 2011, 14:1449-1465.
8. Bains J.S., Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 1997, 25:335-358.
9. Cabungcal J.-H., Preissmann D., Delseth C., Cuenod M., Do K.Q., et al. Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: relevance to schizophrenia. Neurobiol Dis 2007, 26:634-645.
10. Noble M., Smith J., Power J., Mayer-Proschel M. Redox state as a central modulator of precursor cell function. Ann NY Acad Sci 2003, 991:251-271.
11. Li Z., Dong T., Proschel C., Noble M. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function. PLoS Biol 2007, 5:212-231.
12. Prozorovski T., Schulze-Topphoff U., Glumm R., Baumgart J., Schroter F., et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol 2008, 10:385-394.
13. Kamata H., Oka S-i, Shibukawa Y., Kakuta J., Hirata H. Redox regulation of nerve growth factor-induced neuronal differentiation of PC12 cells through modulation of the nerve growth factor receptor, TrkA. Arch Biochem Biophys 2005, 434:16-25.
14. Zimmerman A.K., Loucks F.A., Schroeder E.K., Bouchard R.J., Tyler K.L., et al. Glutathione binding to the Bcl-2 homology-3 domain groove. J Biol Chem 2007, 282:29296-29304.
15. Vaughn A.E., Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome C. Nat Cell Biol 2008, 10:1477-1483.
16. James S.J., Melnyk S., Jernigan S., Cleves M.A., Halsted C.H., et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B 2006, 141B:947-956.
17. Ming X., Johnson W.G., Stenroos E.S., Mars A., Lambert G.H., et al. Genetic variant of glutathione peroxidase 1 in autism. Brain Dev 2010, 32:105-109.
18. Bowers K., Li Q., Bressler J., Avramopoulos D., Newschaffer C., et al. Glutathione pathway gene variation and risk of autism spectrum disorders. J Neurodevelop Disord 2011, 10.1007/s11689-011-9077
19. Williams T.A., Mars A.E., Byske S.G., Stenroos E.S., Wang R., et al. Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. Arch Pediatr Adolesc Med 2007, 161:356-361.
20. Barua M., Jenkins E.C., Chen W., Kuizon S., Pullarkat R.K., et al. Glyoxalase 1 polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity-implications for autism. Autism Res 2011, 4:1-9.
21. Thornalley P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems-role in ageing and disease. Drug Metabol Drug Interact 2008, 23:125-150.
22. Desai K.M., Chang T., Wang H., Banigesh A., Dhar A., et al. Oxidative stress and aging: is methylglyoxal the hidden enemy?. Can J Physiol Pharmacol 2010, 88:273-284.
23. Semba R.D., Nicklett E.J., Ferrucci L. Does accumulation of advance glycation end products contribute to the aging phenotype. J Gernotol 2010, 65A:963-975.
24. Tan D., Wang Y., Lo C.-Y., Sang S., Ho C.-T. Methylglyoxal: its presence in beverages and potential scavengers. Ann N Y Acad Sci 2008, 1126:72-75.
25. Nakayama K., Nakayama M., Terawaki H., Murata Y., Sato T., et al. Carbonated soft drinks and carbonyl stress burden. J Toxicol Sci 2009, 34:699-702.
26. Fleming T.H., Humpert P.M., Nawroth P.P., Bierhaus A. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process-a mini-review. Gerontology 2010, 10.1159/00032208.
27. Yan S.F., Ramasamy R., Schmidt A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009, 87:235-247.
28. Yamawaki H., Saito K., Okada M., Hara Y. Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells. Am J Physiol Cell Physiol 2008, 295:C1510-C1517.
29. Shangari N., Depeint F., Furrer R., Bruce W.R., Popovic M., et al. A thermolyzed diet increases oxidative stress, plasma a-aldehydes and colonic inflammation in the rat. Chem Biol Interac 2007, 169:100-109.
30. Careaga M., Van de Water J., Ashwood P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 2010, 7:283-292.
31. Uribarri J., Woodruff S., Goodman S., Cai W., Chen X.Z., et al. Advanced glycation end products in foods and a practival guide to their reduction in the diet. J Am Diet Assoc 2010, 110:911-916.
32. Uribarri J., Cai W., Sandu O., Peppa M., Goldberg T., et al. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005, 1043:461-466.
33. Birlouez-Aragon I., Saavedra G., Tessier F.J., Galinier A., Ait-Ameur L., et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 2010, 91:1220-1226.
34. Vlassara H., Striker G.E. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011, 10.1038/nrendo.2011.7.
35. Duffey K.J., Popkin B.M. Energy density, portion size and eating occasions: contributions to increased energy intake in the United States, 1977-2006. PLoS Med 2011, 8:e1001050.
36. Cai W., He J.C., Zhu L., Chen X., Zheng F., et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases and lifespan. Am J Pathol 2008, 173:327-336.
37. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002, 99:15596-15601.
38. Stirban A., Negrean M., Gotting C., Uribarri J., Gawlowski T., et al. Dietary advance glycation end products and oxidative stress. Ann N Y Acad Sci 2008, 1126:276-279.
39. Mericq V., Piccardo C., Cai W., Chen X., Zhu L., et al. Maternally transmitted and food-derived glycotoxins. Diabetes Care 2010, 33:2232-2237.
40. Ahmed N., Mirshekar-Syahkal B., Kennish L., Karachalias N., Babaei-Jadidi R., et al. Assay of advanced glycation end products in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol Nutr Food Res 2005, 49:691-699.
41. Wang J., Chang T. Methylglyoxal content in drinking coffee as a cytotoxic factor. J Food Sci 2010, 75:H167-H171.
42. Ankrah N.-A., Appiah-Opong R. Toxicity of low levels of methylglyoxal: depletion og blood glutathione and adverse effect on glucose tolerance in mice. Toxicol Lett 1999, 109:61-67.
43. Rossignol D.A., Frye R.E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry 2011, 10.1038/mp.2010.13.
44. Maher P. The effects of stress and aging on glutathione metabolism. Ageing Res Rev 2005, 4:288-314.
45. Sims N.R., Nilsson M., Muyderman H. Mitochondrial glutathione: a modulator of brain cell death. J Bioenerg Biomembr 2004, 36:329-333.
46. James S.J., Rose S., Melnyk S., Jernigan S., Blossom S., et al. Cellular and mitochondrial gluathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J 2009, 23:2374-2383.
47. Garcia de Arriba S., Stuchbury G., Yarin J., Burnell J., Loske C., et al. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells-protection by carbonyl scavengers. Neurobiol Aging 2007, 28:1044-1050.
48. Morcos M., Du X., Pfisterer F., Hutter H., Sayed A.A.R., et al. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 2008, 7:260-269.
49. Reddy V.P., Zhu X., Perry G., Smith M.A. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 2009, 16:763-774.
50. Matson J.L., Kozlowski A.M. The increasing prevalence of autism spectrum disorders. Res Autism Spectr Disord 2011, 5:418-425.
51. Zapella M. Autistic regression with and without EEG abnormalities followed by favorable outcomes. Brain Dev 2010, 32:739-745.
52. Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288:1723-1727.
53. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
54. Heslehurst N., Ells L.J., Simpson H., Batterham A., Wilkinson J., et al. Trends in maternal obesity incidence rates, demographic predictors and health inequalities in 36,821 women over a 15 year period. Br J Obstet Gynecol 2007, 114:187-194.
55. Mokdad A.H., Ford E.S., Bowman B.A., Nelson D.E., Engelgau M.M., et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000, 23:1278-1283.
56. Cowie C.C., Rust K.F., Ford E.S., Eberhart M.S., Byrd-Holt D.D., et al. Full accounting of diabetes and pre-diabetes in the US population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
57. Lipscombe L.L., Hux J.E. Trends in diabetes prevalence, incidence and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007, 369:750-756.
58. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009, 65:591-598.
59. Lyall K., Pauls D.L., Santangelo S., Spiegelman D., Ascherio A. Maternal early life factors associated with hormone levels and the risk of having a child with an autism spectrum disorder in the Nurses Health Study II. J Autism Dev Disord 2011, 41:618-627.
60. Getahun D., Nath C., Ananth C.V., Chavez M.R., Smulian J.C. Gestational diabetes in the United States: temporal trends 1989-2004. Am J Obstet Gynecol 2008, 198:525.e521-525.e525.
61. Gardener H., Spiegelman D., Buka S.L. Prenatal risk factors for autism: comprehensive meta-analysis. Br J Psychol 2009, 195:7-14.
62. Silverman J.L., Yang M.H., Lord C., Crawley J.N. Behavioral phenotyping assays for mouse models of autism. Nat Rev Neurosci 2010, 11:490-502.